Q3 EPS Estimates for Haemonetics Lowered by Zacks Research

Haemonetics Co. (NYSE:HAE - Free Report) - Zacks Research cut their Q3 2026 earnings per share (EPS) estimates for shares of Haemonetics in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $1.33 for the quarter, down from their previous estimate of $1.34. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q3 2027 earnings at $1.46 EPS.

Other equities analysts also recently issued research reports about the company. Barrington Research cut their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Raymond James restated a "strong-buy" rating and set a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and cut their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Finally, Needham & Company LLC cut their target price on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Haemonetics currently has an average rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Stock Performance

Shares of NYSE:HAE traded up $0.79 during trading on Monday, hitting $70.45. 430,943 shares of the stock were exchanged, compared to its average volume of 678,293. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The company has a market capitalization of $3.38 billion, a price-to-earnings ratio of 27.74, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. Haemonetics has a 1-year low of $55.30 and a 1-year high of $94.99. The company's fifty day simple moving average is $63.77 and its 200-day simple moving average is $69.92.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same quarter last year, the firm earned $0.90 EPS. Haemonetics's revenue for the quarter was down 3.5% compared to the same quarter last year.

Hedge Funds Weigh In On Haemonetics

Several large investors have recently made changes to their positions in HAE. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics during the fourth quarter valued at $25,000. Quarry LP increased its holdings in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares during the last quarter. Covestor Ltd increased its holdings in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. bought a new stake in Haemonetics in the fourth quarter valued at about $62,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in Haemonetics in the first quarter valued at about $65,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.